[Skip to Navigation]
Sign In
Comment & Response
April 30, 2020

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Author Affiliations
  • 1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • 2Sheba Medical Center, Ramat Gan, Israel
  • 3Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
JAMA Oncol. 2020;6(7):1114-1115. doi:10.1001/jamaoncol.2020.0628

To the Editor We read with interest the work by Duan and colleagues1 and commend their remarkable contribution to the evidence base on immunotherapy. Although the use of anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) agents revolutionized cancer treatment, a direct comparison between the classes is still lacking. The authors suggest that anti–PD-1 is superior to anti–PD-L1, lowering the risk of death by 22% and 32% as monotherapy or in combination with standard therapies, respectively.

Add or change institution